Dermatology

Specialty pharmacies may be able to better monitor comorbid conditions in psoriatic arthritis patients.

Ixekizumab fully or partially cleared moderate-to-severe psoriasis in 80% of patients.

Patients with psoriasis who are exposed to physical trauma face an elevated risk of developing psoriatic arthritis.

An experimental biologic known as brodalumab may prove to be an effective treatment for symptoms of psoriasis.

Recent study results have suggested that patients with psoriasis are at higher risk of developing major depression than those without the inflammatory skin condition.

Tofacitinib citrate (Xeljanz) treats adults with active psoriatic arthritis.

Dupilumab plus topical corticosteroids shows positive results in patients with inadequately controlled moderate-to-severe atopic dermatitis.

Approximately half of patients who received a high dose of the stem cells had reduced symptoms.

Conflicting opinions exist between the National Eczema Association and ITSAN about the safety of topical corticosteroids.

Psoriatic Arthritis Impact of Disease test can be administered via a touch screen.

Study evaluates whether etanercept monotherapy treats psoriatic arthritis as effectively as the combination of etanercept and methotrexate.

Almost half of Medicare patients taking biologic therapies for moderate-to-severe plaque psoriasis stop treatment within a year.

Certolizumab pegol is a safe alternative tumor necrosis factor-a inhibitor with some benefits for psoriatic arthritis patients.

An interaction between CARD14 and MALT1 creates increased immune response and inflammation in patients with psoriasis.

Study evaluates whether smoking cigarettes worsens clinical damage in PsA patients as it does in rheumatoid arthritis and ankylosing spondylitis.

Ixekizumab found safe and effective for short term treatment of moderate-to-severe plaque-type psoriasis.

Evaluating prior unsuccessful therapies could potentially improve psoriasis treatment.

Duration of psoriasis at baseline impacts the odds of developing erosion in psoriatic arthritis.

Tofacitinib may offer an effective oral option for patients with psoriatic arthritis.

Study finds 15.5% of all psoriasis patients had undiagnosed psoriatic arthritis.

AbbVie and Boehringer Ingelheim have announced a global collaboration to develop and commercialize BI 655066, an anti-IL-23 monoclonal biologic antibody in Phase 3 development for psoriasis.

Tofacitinib is an oral Janus kinase inhibitor that improves the signs and symptoms of psoriatic arthritis.

The oral Janus kinase inhibitor tofacitinib treats adults with active psoriatic arthritis (PsA).

The FDA has approved Eli Lilly and Company's ixekizumab (Taltz) as a treatment for moderate to severe plaque psoriasis.

Ixekizumab (Taltz) approved for moderate-to-severe plaque psoriasis in adults.